Journal
CLINICAL MICROBIOLOGY REVIEWS
Volume 27, Issue 1, Pages 68-88Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/CMR.00046-13
Keywords
-
Categories
Funding
- North West England Medical Research Council Fellowship Scheme in Clinical Pharmacology and Therapeutics
- Medical Research Council [G1000417/94909]
- ICON
- GlaxoSmithKline
- AstraZeneca
- Medical Evaluation Unit
- Gilead Sciences
- Pfizer Inc
- Astellas
- Merck
- F2G
- MRC [G1000417] Funding Source: UKRI
- Medical Research Council [G1000417] Funding Source: researchfish
- National Institute for Health Research [CS/08/08/10] Funding Source: researchfish
Ask authors/readers for more resources
Understanding the tissue penetration of systemically administered antifungal agents is critical for a proper appreciation of their antifungal efficacy in animals and humans. Both the time course of an antifungal drug and its absolute concentrations within tissues may differ significantly from those observed in the bloodstream. In addition, tissue concentrations must also be interpreted within the context of the pathogenesis of the various invasive fungal infections, which differ significantly. There are major technical obstacles to the estimation of concentrations of antifungal agents in various tissue subcompartments, yet these agents, even those within the same class, may exhibit markedly different tissue distributions. This review explores these issues and provides a summary of tissue concentrations of 11 currently licensed systemic antifungal agents. It also explores the therapeutic implications of their distribution at various sites of infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available